PDE4DIP and cancer: Using the CCLE mutation dataset containing 27/38 bortezomib-insensitive and 22/49 bortezomib-sensitive cancer cell lines, we were able to show consistently elevated mutation frequencies for 18/19 genes (not PDE4DIP) in bortezomib-insensitive cell lines compared to bortezomib-sensitive cell lines.